| [1] |
Cameron D, Piccart-Gebhart MJ, Gelber RD，et al. 11 years’ follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial[J]. Lancet，2017，389(10075):1195-1205.
|
| [2] |
George JN, Raskob GE, Shah SR, et al. Drug-induced thrombocytopenia: a systematic review of published case reports[J]. Ann Intern Med，1998，129(11):886-890.
|
| [3] |
Baselga J, Carbonell X, Castañeda-Soto NJ, et al. Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule[J]. J Clin Oncol，2005，23(10):2162-2171.
|
| [4] |
Hudis CA. Trastuzumab--mechanism of action and use in clinical practice[J]. N Engl J Med，2007，357(1):39-51.
|
| [5] |
Uppal H, Doudement E, Mahapatra K, et al. Potential mechanisms for thrombocytopenia development with trastuzumab emtansine (T-DM1)[J]. Clin Cancer Res，2015，21(1):123-133.
|
| [6] |
Aster RH. Drug-induced immune thrombocytopenia: an overview of pathogenesis[J]. Semin Hematol，1999，36(1 Suppl 1):2-6.
|
| [7] |
Liu XG, Bai XC, Chen FP, et al. Chinese guidelines for treatment of adult primary immune thrombocytopenia[J]. Int J Hematol，2018，107(6):615-623.
|
| [8] |
Mantzourani M, Gogas H, Katsandris A, et al. Severe thrombocytopenia related to trastuzumab infusion[J]. Med Sci Monit, 2011，17(7):CS85-CS87.
|
| [9] |
Cathomas R, Goldhirsch A, von Moos R. Drug-induced immune thrombocytopenia[J]. N Engl J Med，2007，357(18):1870-1871.
|
| [10] |
Parikh O, Neave F, Palmieri C. Severe thrombocytopenia induced by a single infusion of trastuzumab[J]. Clin Breast Cancer，2008，8(3):285-286.
|
| [11] |
Drudi F, Gianni L, Fantini M, et al. Trastuzumab-related thrombocytopenia: always a self-limiting complication？[J]. Ann Oncol，2010，21(3):668-669.
|
| [12] |
Jara Sánchez C, Olier Gárate C, García-Donas Jiménez J, et al. Drug-induced thrombocytopenia induced by trastuzumab: a special challenge in a curable disease[J]. Ann Oncol，2009，20(9):1607-1608.
|
| [13] |
Pino MS, Angiolini C, Fioretto L. Severe thrombocytopenia after trastuzumab retreatment: a case report[J]. BMC Res Notes，2013，6:400.
|
| [14] |
Aguirre E, Taberner T, Luaña A，et al. Severe thrombocytopenia related to long-term trastuzumab exposure[J]. Tumori，2013，99(1):e1-e2.
|
| [15] |
Zeng RC, Dai XX, Xie FY et al. Severe thrombocytopenia induced by second exposure to trastuzumab can be alleviated by prolonging the interval between treatments[J]. Clin Breast Cancer，2014，14(2):e69-e72.
|
| [16] |
Miarons M, Velasco M, Campins L，et al. Gradual thrombocytopenia induced by long-term trastuzumab exposure[J]. J Clin Pharm Ther，2016，41(5):563-565.
|
| [17] |
Luo Q, Guo Z, Ye C. Thrombocytopenia induced by herceptin[J]. Am Surg，2019, 85(4):e222-224.
|
| [18] |
Zeng XQ, Jiang SS, Peng YY，et al. Trastuzumab-induced severe thrombocytopenia: a case report and literature review[J]. Chin Med Sci J，2020，35(4):377-382.
|
| [19] |
Zhou Q, Dong J, Jiang X，et al. Trastuzumab-induced thrombocytopenia after eight cycles of trastuzumab treatment[J]. Open Med (Wars)，2020，15(1):659-662.
|
| [20] |
Wang X, Zhu X, Zou J, et al. Severe thrombocytopenia induced by trastuzumab rechallenge: a case report and literature review[J]. J Clin Pharm Ther，2021，46(4):1173-1177.
|
| [21] |
Cathomas R, von Moos R. Severe drug-induced thrombocytopenia after treatment with trastuzumab but not with lapatinib[J]. Ann Oncol，2009，20(9):1606-1607.
|